Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ACLY | P53396 | 4/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL49544 | 0.82 | CA1 (0.58) | MEN1MAPTKMT2ACYP3A4TSHR | |
| SCHEMBL442971 | 0.82 | TSHR (0.58) | MEN1MAPTKMT2APLA2G1BATG4B | |
| SCHEMBL4396495 | 0.80 | ALDH1A1 (0.52) | MAPTKMT2ACYP3A4TSHRHSD17B10 | |
| SCHEMBL8354359 | 0.77 | NMT1 (0.39) | MEN1MAPTKMT2AACLYPLA2G1B | |
| SCHEMBL13855828 | 0.76 | SIRT1 (0.42) | MEN1MAPTKMT2ACYP3A4TSHR | |
| SCHEMBL981236 | 0.75 | CYP3A4 (0.40) | MEN1MAPTKMT2AACLYCYP3A4 | |
| SCHEMBL670489 | 0.75 | CYP3A4 (0.65) | MEN1MAPTKMT2ACYP3A4TSHR | |
| SCHEMBL13550074 | 0.75 | NMT1 (0.38) | MEN1MAPTKMT2AACLYPLA2G1B | |
| SCHEMBL4644670 | 0.75 | TSHR (0.65) | MEN1MAPTKMT2ACYP3A4TSHR | |
| SCHEMBL16599884 | 0.75 | TSHR (0.43) | MEN1MAPTKMT2AACLYPLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | claimed |
| CN-1157386-C | Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections | ղɭҩҵ����˾ | 2004-07-14 | — | — | CN | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| CN-1295566-A | Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections | JANSSEN PHARMACEUTICA NV (BE) | 2001-05-16 | — | — | CN | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| EP-0488860-B1 | Method for the production of polyalkoxylated aromatic compounds | RHONE POULENC CHIMIE (FR) | 1995-10-11 | — | — | EP | claimed |
| CN-122055358-A | GPR65 small molecule regulator and preparation method and application thereof | 四川大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | MERCK SHARP & DOHME LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-4879391-A | 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents | PFIZER INC. (US) | 1989-11-07 | — | — | US | disclosed |
| US-4861880-A | 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents | PFIZER INC. (US) | 1989-08-29 | — | — | US | disclosed |
| EP-0104860-B1 | 1-PHENYL-2(1H,3H)-INDOLONE PSYCHO-THERAPEUTIC AGENTS | PFIZER INC. (US) | 1987-03-18 | — | — | EP | disclosed |
| US-4476307-A | Heteroylidene indolone compounds | PFIZER INC. (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0104860-A1 | 1-Phenyl-2(1H,3H)-indolone psycho-therapeutic agents | PFIZER INC. (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | MEN1 4382/4885MAPT 4642/4885KMT2A 4152/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | MEN1 2996/4885MAPT 4803/4885KMT2A 4351/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | MEN1 4238/4885MAPT 2776/4885KMT2A 4296/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | MEN1 2993/4885MAPT 4737/4885KMT2A 4631/4885 |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | TYMP, PNP, CD4 | MEN1 4689/4885MAPT 1869/4885KMT2A 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.